SEC Tracker
Get the app
RNAC · XBRL financial data

Cartesian Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (RNAC's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023†Mar 31, 2024†Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue6,5518,266*5,84033,445387(759)*1,100298452947*780
Revenue from contracts with customers6,5518,266*5,84033,2710(836)*400000*00
Research and development13,00222,431*9,73812,66111,40011,306*14,67414,86913,80214,689*19,46320,431
General and administrative6,61422,167*9,4507,0276,5627,087*8,3157,2407,7168,197*7,1148,724
Total operating expenses19,61644,598*19,18819,68817,96225,972*22,98922,10921,51879,586*26,57729,155
Operating income (loss)(13,065)(36,332)*(13,348)13,757(17,575)(26,731)*(21,889)(21,811)(21,066)(78,639)*(26,499)(29,155)
Interest income—year only———year only2,0151,748—year only1,0261,103
Interest expense1,2730*0000*—0———852
Other income (expense)253(62)*508292250(444)*0(5)0(2,005)*(3)126
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)(9,002)(177,658)*(56,824)13,836(24,183)(10,253)*(17,710)15,886(35,902)(92,576)*(39,182)15,769
Earnings per share, basic‡ USD per share(1.80)—(315.32)0.58(1.13)—(0.68)0.51(1.38)(3.56)*(1.46)0.47
Earnings per share, diluted‡ USD per share(1.80)—(315.32)0.54(1.13)—(0.68)0.50(1.38)(3.62)*(1.46)0.46
Weighted average shares, basic‡ thousands of shares5,1555,288*18016,72321,471—25,90325,98026,00326,006*26,85529,467
Weighted average shares, diluted‡ thousands of shares5,1555,288*18017,79121,471—25,90326,44726,00325,544*26,85529,861
  • ‡ Per-share figures and share counts are adjusted for the 1-for-30.030030030030026 stock split (April 2024); filings made before it reported them unadjusted.
  • † Share count changed about 1/9 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 36x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (RNAC's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023†Mar 31, 2024†Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents79,60376,911103,41887,227219,198212,610180,434160,324143,384125,139118,641147,606
Marketable securities00——————————
Accounts receivable4,8985,8702,00632,0394,8298721,7653547221,115261196
Prepaid and other current assets3,4934,9673,3152,0444,1293,1442,9212,7173,1543,0223,1375,813
Total current assets89,86990,729111,109124,782229,136216,626185,120163,395147,260129,276122,039153,615
Property and equipment, net2,4212,1132,4026,67210,2259,91210,17412,28512,39412,18511,63711,311
Right-of-use asset10,33910,0689,55613,85213,5235,5355,3515,1644,9725,6015,3665,124
Goodwill—48,16348,16348,16348,16348,16348,16348,16348,16348,16348,16348,163
Total assets106,034305,050325,207347,738455,316435,023409,130388,893372,675296,411288,391318,628
Accounts payable3753,1502,5172,8625172882,0974542,2251,2881,5981,046
Accrued liabilities13,63714,7338,92710,6159,36312,0769,1978,0127,7029,49810,16115,142
Total current liabilities19,93968,20936,65426,11521,40522,97614,99812,25613,80314,93715,94520,550
Long-term debt—————————0—52,851
Lease liability, non-current8,6948,7898,22812,34411,88111,13310,3629,5598,7278,5257,6696,805
Total liabilities45,705444,680442,007449,196454,564441,825430,919391,420408,519422,651436,509443,854
Accumulated deficit(436,989)(614,647)(671,471)(657,635)(681,818)(692,071)(709,781)(693,895)(729,797)(822,373)(861,555)(845,786)
Total stockholders' equity60,329(440,184)(116,800)(101,458)752(6,802)(21,789)(2,527)(35,844)(126,240)(148,118)(125,226)
Total liabilities and equity106,034305,050325,207347,738455,316435,023409,130388,893372,675296,411288,391318,628
Common shares outstanding (cover page)‡ thousands of shares5,1685,39359321,38225,41525,90725,95426,00226,00426,50929,38230,255
  • ‡ Per-share figures and share counts are adjusted for the 1-for-30.030030030030026 stock split (April 2024); filings made before it reported them unadjusted.
  • † Share count changed about 1/9 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 36x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (RNAC's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023†Mar 31, 2024†Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(9,002)(177,658)*(56,824)13,836(24,183)(10,253)*(17,710)15,886(35,902)(92,576)*(39,182)15,769
Stock-based compensation2,321*14,144*1,4311,591*1,695*1,865*2,5083,279*2,590*2,144*2,4232,083*
Net cash from operating activities(9,215)*(23,286)*(15,917)(14,446)*13,691*(7,002)*(23,108)(17,521)*(15,600)*(17,712)*(22,135)(21,082)*
Purchases of property and equipment0*64*6021,587*6,199*705*1,0752,595*1,292*492*27272*
Net cash from investing activities0*6,497*(602)(1,587)*(6,199)*(354)*(1,075)(2,595)*(1,292)*(492)*(27)(272)*
Proceeds from issuing common stock——————00*——15,3923,916*
Repayments of long-term debt24,871*0*——0*0*——————
Net cash from financing activities(24,789)*14,081*43,031120*124,494*783*(8,025)60*(38)*(52)*15,67150,344*
Net change in cash(34,024)*(2,692)*26,507(15,899)*131,971*(6,588)*(32,176)(20,044)*(16,940)*(18,245)*(6,498)28,965*
  • † Share count changed about 1/9 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 36x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Cartesian Therapeutics147,6060(21,082)*30.3M7.0 quarters 10-QJun 30, 2026
Galectin Therapeutics13,269not reported(2,439)*100.8M5.4 quarters 10-QJun 30, 2026
Atossa Therapeutics26,094not reported(9,644)*10.0M2.7 quarters 10-QJun 30, 2026
Enanta Pharmaceuticals33,41914,359(9,972)*29.1M19.0 quarters 10-QJun 30, 2026
TuHURA Biosciences996not reported(8,634)*63.7M0.1 quarters 10-QJun 30, 2026
Fennec Pharmaceuticals41,24917,87450*35.1M— 10-QJun 30, 2026
Protara Therapeutics17,076not reported(15,389)*59.1M9.3 quarters 10-QJun 30, 2026
Caribou Biosciences26,1941,499(22,787)*107.2M4.9 quarters 10-QJun 30, 2026
Fate Therapeutics32,4292,082(23,400)119.8M6.6 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.